Skip to content

Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company that uses generative AI to discover and develop drugs, offering a suite of tools for target discovery, molecule generation, and clinical trial prediction.

60

Overview

Insilico Medicine is a clinical-stage biotechnology company that applies generative artificial intelligence to drug discovery and development, aiming to extend healthy productive longevity. Its Pharma.AI platform provides a suite of tools that span target identification, molecule generation, and clinical trial prediction, serving researchers and pharmaceutical teams seeking to reduce the time and cost of bringing new therapies to patients.

Target Discovery and Disease Modeling

PandaOmics drives the discovery and prioritization of novel drug targets by analyzing multiomics data. It supports disease modeling and target identification, helping researchers uncover biological pathways that could lead to new treatments. The platform integrates with other components of Pharma.AI, enabling a seamless flow from target hypothesis to experimental validation.

Generative Chemistry and Molecular Design

Chemistry42 generates novel molecules with desired properties. It includes Alchemistry, a physics-based relative binding free energy engine that evaluates molecular interactions. ADMET and off-target predictions allow on-the-fly optimization, while MDFlow provides end-to-end simulation workflows. Retrosynthesis predicts synthetic routes for molecular structures, and MolSpace visualizes generated results using generative topographic mapping for comparison with public data. Nach01, a multimodal natural and chemical languages foundation model, further enhances molecular design capabilities.

Clinical Trial Design and Prediction

inClinico is designed to predict clinical trial outcomes and assist in trial design. By analyzing historical trial data and biological insights, it helps researchers prioritize candidates and optimize protocols, potentially increasing the probability of success in later stages. This tool complements the preclinical discovery process, offering a bridge to clinical development.

Longevity and Multiomics AI

The Precious series of models focuses on aging and longevity. Precious1GPT predicts biological age and identifies targets from multiomics data. Precious2GPT synthesizes multimodal multiomics data, while Precious3GPT serves as a multi-tissue, multispecies, multiomics, multimodal life model. The Virtual Aging Cell is a multi-agent virtual cell that uses biological age as a core condition, enabling simulations of aging processes and interventions.

Research Assistance and Automation

DORA is a multi-agent generative research assistant that supports scientific inquiry. Life Star 2 provides an automated lab operating environment, streamlining experimental workflows. The Data Warehouse ensures cross-application data flow through efficient integration and standardization. Additionally, MCPs (Model Context Protocol servers) expose Pharma.AI tools to agents, and Skills + Agents offer agentic workflows built on the Pharma.AI stack.

Benchmarks and Model Development

PSI Frontier offers resources for model evaluation and development. Science MMAI Gym boosts foundation model intelligence in drug discovery, while Models provides frontier state-of-the-art models for pharma. DDD Benchmark evaluates model capability across the drug discovery and development process, and ScienceAI Bench assesses broader scientific reasoning across biology, chemistry, and longevity. These tools support the training and benchmarking of AI models, fostering transparency and progress in the field.

Environmental Sustainability

Insilico Medicine also applies generative AI technologies to environmental sustainability, exploring ways to address ecological challenges through computational approaches. This initiative reflects the company's broader mission to leverage AI for societal benefit beyond human health.

Insilico Medicine's platform is grounded in peer-reviewed research and a clinical pipeline that includes Rentosertib, a drug candidate currently in Phase III trials for idiopathic pulmonary fibrosis. The company's integrated approach aims to transform drug discovery by combining generative AI with automation and multiomics analysis, offering a comprehensive toolkit for researchers and pharmaceutical partners.

Core features

  • PandaOmics for target discovery and prioritization
  • Generative Biologics for biomolecule optimization
  • Chemistry42 for generative chemistry and molecular design
  • Alchemistry for physics-based binding free energy calculations
  • inClinico for clinical trial design and prediction
  • Precious1GPT, Precious2GPT, and Precious3GPT for multiomics age prediction and data synthesis
  • DORA, a multi-agent generative research assistant
  • MCPs exposing Pharma.AI tools to agents

Use cases

  1. 1Identifying and validating novel drug targets
  2. 2Generating and optimizing small molecules and biologics
  3. 3Predicting clinical trial outcomes to inform trial design
  4. 4Analyzing multiomics data for aging research and target identification
  5. 5Automating laboratory operations with Life Star 2
  6. 6Simulating molecular dynamics and retrosynthesis

Strengths and things to check

Strengths

  • Integrated platform covering multiple stages of drug discovery
  • Backed by peer-reviewed research and a clinical pipeline
  • Includes specialized tools for longevity and multiomics analysis
  • Offers benchmarks and model training resources for AI development

Things to check

  • Platform complexity may require specialized expertise
  • Some tools are in active development and may not be broadly validated
  • Access and pricing details are not publicly disclosed
  • Reliance on AI predictions should be complemented with experimental validation

Pricing

Subscription pricing is not listed.

Basic information

Added
Oct 10, 2026
Platforms
Web
Chinese & English
Not marked
API
Marked as supported
Self-hosting
Not marked
Best for
Biotechnology and pharmaceutical researchers, computational chemists, and drug discovery teams focused on accelerating therapeutic development.
Information updated
Oct 16, 2026
Website status
Checking
Corrections · Privacy · Data requests?
Contact us

Features, pricing and availability may change. Always verify details on the official website. Maintained by steven · Last updated Oct 16, 2026 →

Related tools

All categories